中國核能科技(00611.HK)接受由貸款人發出的融資函件的補充函件
格隆匯4月26日丨中國核能科技(00611.HK)發佈公吿,於2020年6月2日,公司(作為借款人)與香港一間持牌銀行(作為貸款人)訂立融資函件,據此,貸款人同意向公司提供一項金額最高8000萬港元的循環貸款融資。
於2022年4月26日,公司(作為借款人)接受由貸款人發出的融資函件的補充函件,據此,(其中包括)(i)融資函件的到期日將延長至2023年4月25日;(ii)融資的最高金額將從港幣8000萬元提高至港幣1億元;(iii)公司將不再需要承諾中核集團須維持其於公司的直接或間接股權不少於30%並繼續為公司單一主要股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.